Evaluation of Three Multiplex Real-time Reverse Transcription PCR Assays for Simultaneous Detection of SARS-CoV-2, Influenza A/B, and Respiratory Syncytial Virus in Nasopharyngeal Swabs

J Korean Med Sci. 2021 Dec 13;36(48):e328. doi: 10.3346/jkms.2021.36.e328.

Abstract

Background: In the coronavirus disease 2019 (COVID-19) pandemic era, the simultaneous detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus (Flu), and respiratory syncytial virus (RSV) is important in the rapid differential diagnosis in patients with respiratory symptoms. Three multiplex real-time reverse transcription polymerase chain reaction (rRT-PCR) assays have been recently developed commercially in Korea: PowerChek™ SARS-CoV-2, Influenza A&B Multiplex Real-time PCR Kit (PowerChek; KogeneBiotech); STANDARD™ M Flu/SARS-CoV-2 Real-time Detection Kit (STANDARD M; SD BioSensor); and Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay (Allplex; Seegene). We evaluated the analytical and clinical performances of these kits.

Methods: A limit of detection tests were performed and cross-reactivity analysis was executed using clinical respiratory samples. Ninety-seven SARS-CoV-2-positive, 201 SARS-CoV-2-negative, 71 influenza A-positive, 50 influenza B-positive, 78 RSV-positive, and 207 other respiratory virus-positive nasopharyngeal swabs were tested using the three assays. The AdvanSure™ respiratory viruses rRT-PCR assay (AdvanSure; LG Life Sciences) was used as a comparator assay for RSV.

Results: Except in influenza B, in SARS-CoV-2 and influenza A, there were no significant differences in detecting specific genes of the viruses among the three assays. All three kits did not cross-react with common respiratory viruses. All three kits had greater than 92% positive percent agreement and negative percent agreement and ≥ 0.95 kappa value in the detection of SARS-CoV-2 and flu A/B. Allplex detected RSV more sensitively than AdvanSure.

Conclusion: The overall performance of three multiplex rRT-PCR assays for the concurrent detection of SARS-CoV-2, influenza A/B, and RSV was comparable. These kits will promote prompt differential diagnosis of COVID-19, influenza, and RSV infection in the COVID-19 pandemic era.

Keywords: Influenza A Virus; Influenza B Virus; Multiplex Polymerase Chain Reaction; Respiratory Syncytial Viruses; SARS-CoV-2.

Publication types

  • Evaluation Study

MeSH terms

  • COVID-19 / diagnosis*
  • COVID-19 / virology
  • Cross Reactions
  • Humans
  • Influenza A virus / genetics
  • Influenza A virus / isolation & purification
  • Influenza B virus / genetics
  • Influenza B virus / isolation & purification
  • Influenza, Human / diagnosis*
  • Influenza, Human / virology
  • Limit of Detection
  • Multiplex Polymerase Chain Reaction / methods*
  • Nasopharynx / virology*
  • Nucleocapsid Proteins / genetics
  • Polyproteins / genetics
  • RNA, Viral / analysis*
  • RNA, Viral / metabolism
  • Reagent Kits, Diagnostic
  • Republic of Korea
  • Respiratory Syncytial Virus Infections / diagnosis*
  • Respiratory Syncytial Virus Infections / virology
  • Respiratory Syncytial Virus, Human / genetics
  • Respiratory Syncytial Virus, Human / isolation & purification
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / isolation & purification
  • Viral Matrix Proteins / genetics
  • Viral Proteins / genetics

Substances

  • M1 protein, Influenza A virus
  • Nucleocapsid Proteins
  • ORF1ab polyprotein, SARS-CoV-2
  • Polyproteins
  • RNA, Viral
  • Reagent Kits, Diagnostic
  • Viral Matrix Proteins
  • Viral Proteins
  • nucleoprotein, influenza B virus

Grants and funding